In their press release, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that an ongoing Phase II proof-of-concept trial evaluating an investigational 8 mg dose of… Read More »Regeneron announces that its high-dose aflibercept (8mg) has met primary end-point in Phase II data for wet AMD.
Researchers from King’s College London, UK have published a systematic review and meta-analysis on individual participant data from RCT literature using evidence on ocriplasmin’s effect… Read More »A systematic review and meta-analysis on individual participant data, within 5 RCTs, on the treatment of ocriplasmin for vitreomacular adhesion resolution.
A recent research presentation from a clinical ophthalmology group in UCLA has reported that “e-cigarette” smoking is associated with visual impairment in the Behavioral Risk… Read More »Survey data on E-cigarette use from >1 million participants shows concerns about visual impairment.
September 5th, 2021: “EURETINA-Brief”© Issue No. 242 by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the… Read More »
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”) have announced a collaboration on the development of a therapy for Stargardt… Read More »Aequus Pharmaceuticals Inc and reVision Therapeutics collaborate on Stargardt disease therapy treatment.
Researchers led at the Karl Landsteiner Institute for Retinal Research and Imaging, Vienna, Austria, have reported that the discontinuation of treatment on exudative neovascular age… Read More »Treatment discontinuation of anti-VEGF administration during the COVID-19 pandemic has deteriorated visual acuity.
A clinical research team, based at the Nuffield Laboratory of Ophthalmology, John Radcliffe Hospital, Oxford, has published a report on the treatment of RNAi effectors… Read More »Atypical RNA interference effectors – mirtrons – may be applicable for replacement genes treating dominant retinitis pigmentosa (RP).
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 18th, 2021 edition of EURETINA’s web-based digital magazine,… Read More »August 18th, 2021: “EURETINA-Brief”© Issue No. 241
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported vision improvements for advanced retinitis pigmentosa (RP) patients after one year following a single… Read More »Nanoscope Therapeutics Inc., have announced positive results from a phase 1/2a study for optogenetic therapy
A clinical research team, based at the Federal University of São Paulo, Brazil, has reported that COVID-19 proteins have been identified within cells of the… Read More »SARS-CoV-2 virus particles were detected in the human retina in patients with COVID-19